Frontiers in pruritus research: Scratching the brain for more effective itch therapy

Journal of Clinical Investigation

Volumn 116, Issue 5, 2006, Pages 1174-1185

  Paus, Ralf ^a,e   Schmelz, Martin ^b   Bíró, Tamás ^c   Steinhoff, Martin ^d  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF DEBRECEN   (Hungary)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIPRURITIC AGENT; CANNABINOID; CYTOKINE; HISTAMINE RECEPTOR; NEUROTROPHIN; OPIATE; OPIATE RECEPTOR; PROTEINASE; VANILLOID RECEPTOR;

HUMAN; MEDICAL RESEARCH; NEUROENDOCRINOLOGY; NEUROIMMUNOLOGY; NEUROPHYSIOLOGY; NOCICEPTION; PATHOGENESIS; PRIORITY JOURNAL; PRURITUS; REVIEW; SKIN INFLAMMATION; SKIN PAIN; SKIN SENSITIZATION; SPINOTHALAMIC TRACT;

ANIMALS; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; MODELS, NEUROLOGICAL; NEURAL PATHWAYS; PRURITUS; SKIN DISEASES;

EID: 33646418808     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI28553     Document Type: Review

References (125)

1. Greaves, M.W., and Khalifa, N. 2004. Itch: more than skin deep. Int. Arch. Allergy Immunol. 135:166-172.
2. Graham, D.T., Goodell, H., and Wolff, H.G. 1951. Neural mechanisms involved in itch, itchy skin, and tickle sensations. J. Clin. Invest. 30:37-49.
3. Yosipovitch, G., Greaves, M.W., and Schmelz, M. 2003. Itch. Lancet. 361:690-694.
4. Biro, T., et al. 2005. How best to fight that nasty itch - from new insights into the neuroimmunological, neuroendocrine, and neurophysiological bases of pruritus to novel therapeutic approaches. Exp. Dermatol. 14:225-240.
5. Steinhoff, M., et al. 2006. Neurophysiological, neuroimmunological and neuroendocrine basis of pruritus. J. Invest. Dermatol. In press.
6. Twycross, R., et al. 2003. Itch: scratching more than the surface. QJM. 96:7-26.
7. Bromm, B., Scharein, E., and Vahle-Hinz, C. 2000. Cortex areas involved in the processing of normal and altered pain. Prog. Brain Res. 129:289-302.
8. Schmelz, M. 2001. A neural pathway for itch. Nat. Neurosci. 4:9-10.
9. Andrew, D., and Craig, A.D. 2001. Spinothalamic lamina I neurons selectively sensitive to histamine: a central neural pathway for itch. Nat. Neurosci. 4:72-77.
10. Stander, S., and Steinhoff, M. 2002. Pathophysiology of pruritus in atopic dermatitis: an overview. Exp. Dermatol. 11:12-24.
11. Schmelz, M., Schmidt, R., Bickel, A., Handwerker, H.O., and Torebjork, H.E. 1997. Specific C-receptors for itch in human skin. J. Neurosci. 17:8003-8008.
12. Klein, P.A., and Clark, R.A. 1999. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch. Dermatol. 135:1522-1525.
13. Munday, J., et al. 2002. Chlorpheniramine is no more effective than placebo in relieving the symptoms of childhood atopic dermatitis with a nocturnal itching and scratching component. Dermatology. 205:40-45.
14. Rukwied, R., Lischetzki, G., McGlone, F., Heyer, G., and Schmelz, M. 2000. Mast cell mediators other than histamine induce pruritus in atopic dermatitis patients: a dermal microdialysis study. Br. J. Dermatol. 142:1114-1120.
15. Hanifin, J.M. 1990. The role of antihistamines in atopic dermatitis. J. Allergy Clin. Immunol. 86:666-669.
16. Imaizumi, A., Kawakami, T., Murakami, F., Soma, Y., and Mizoguchi, M. 2003. Effective treatment of pruritus in atopic dermatitis using H1 antihistamines (second-generation antihistamines): changes in blood histamine and tryptase levels. J. Dermatol. Sci. 33:23-29.
17. Monroe, E.W. 1992. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis. Clin. Ther. 14:17-21.
18. Arck, P.C., Slominski, A., Theoharides, T.C., Peters, E.M.J., and Paus, R. 2006. Neuroimmunology of stress: skin takes center stage. J. Invest. Dermatol. 126. In press.
19. Paus, R., Theoharides, T.C., and Arck, P.C. 2006. Neuroimmunoendocrine circuitry of the 'brainskin connection'. Trends Immunol. 27:32-39.
20. Botchkarev, N.V., et al. 2006. Neurotrophins in skin biology. J. Invest. Dermatol. 2:31-36.
21. Lee, M.R., and Shumack, S. 2005. Prurigo nodularis: a review. Australas. J. Dermatol. 46:211-218; quiz 219-220.
22. Johansson, O., Liang, Y., and Emtestam, L. 2002. Increased nerve growth factor- and tyrosine kinase A-like immunoreactivities in prurigo nodularis skin - an exploration of the cause of neurohyperplasia. Arch. Dermatol. Res. 293:614-619.
23. Tanaka, A., and Matsuda, H. 2005. Expression of nerve growth factor in itchy skins of atopic NC/NgaTnd mice. J. Vet. Med. Sci. 67:915-919.
24. Aloe, L. 2004. Rita Levi-Montalcini: the discovery of nerve growth factor and modern neurobiology. Trends Cell Biol. 14:395-399.
25. Groneberg, D.A., et al. 2005. Gene expression and regulation of nerve growth factor in atopic dermatitis mast cells and the human mast cell line-1. J. Neuroimmunol. 161:87-92.
26. Toyoda, M., et al. 2002. Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br. J. Dermatol. 147:71-79.
27. Bell, J.K., McQueen, D.S., and Rees, J.L. 2004. Involvement of histamine H4 and H1 receptors in scratching induced by histamine receptor agonists in Balb C mice. Br. J. Pharmacol. 142:374-380.
28. Seike, M., Ikeda, M., Kodama, H., Terui, T., and Ohtsu, H. 2005. Inhibition of scratching behavior caused by contact dermatitis in histidine decarboxylase gene knockout mice. Exp. Dermatol. 14:169-175.
29. Rees, J., and Murray, C.S. 2005. Itching for progress. Clin. Exp. Dermatol. 30:471-473.
30. Schmelz, M., et al. 2003. Active "itch fibers" in chronic pruritus. Neurology. 61:564-566.
31. Andrew, D., Schmelz, M., and Ballantyne, J.C. 2003. Itch - mechanisms and mediators. In Progress in pain research and management. J.O. Dostrovsky, D.B. Carr, and M. Koltzenburg, editors. ISAP Press. Seattle, Washington, USA. 213-226.
32. Schmelz, M., et al. 2003. Chemical response pattern of different classes of C-nociceptors to pruritogens and algogens. J. Neurophysiol. 89:2441-2448.
33. Weidner, C., et al. 1999. Functional attributes discriminating mechanoinsensitive and mechanoresponsive C nociceptors in human skin. J. Neurosci. 19:10184-10190.
34. Schmidt, R., Schmelz, M., Weidner, C., Handwerker, H.O., and Torebjork, H.E. 2002. Innervation territories of mechanoinsensitive C nociceptors in human skin. J. Neurophysiol. 88:1859-1866.
35. Schmelz, M., et al. 2000. Which nerve fibers mediate the axon reflex flare in human skin? Neuroreport. 11:645-648.
36. Ikoma, A., Handwerker, H., Miyachi, Y., and Schmelz, M. 2005. Electrically evoked itch in humans. Pain. 113:148-154.
37. Darsow, U., et al. 2001. New aspects of itch pathophysiology: component analysis of atopic itch using the 'Eppendorf Itch Questionnaire'. Int. Arch. Allergy Immunol. 124:326-331.
38. Darsow, U., et al. 2000. Processing of histamine-induced itch in the human cerebral cortex: a correlation analysis with dermal reactions. J. Invest. Dermatol. 115:1029-1033.
39. Craig, A.D. 2002. How do you feel? Interoception: the sense of the physiological condition of the body. Nat. Rev. Neurosci. 3:655-666.
40. Hsieh, J.C., et al. 1994. Urge to scratch represented in the human cerebral cortex during itch. J. Neurophysiol. 72:3004-3008.
41. Drzezga, A., et al. 2001. Central activation by histamine-induced itch: analogies to pain processing: a correlational analysis of O-15 H2O positron emission tomography studies. Pain. 92:295-305.
42. Mochizuki, H., et al. 2003. Imaging of central itch modulation in the human brain using positron emission tomography. Pain. 105:339-346.
43. Vogt, B.A., Vogt, L., and Laureys, S. 2006. Cytology and functionally correlated circuits of human posterior cingulate areas. Neuroimage. 29:452-466.
44. Apkarian, A.V., Bushnell, M.C., Treede, R.D., and Zubieta, J.K. 2005. Human brain mechanisms of pain perception and regulation in health and disease. Eur. J. Pain. 9:463-484.
45. Walter, B., et al. 2005. Brain activation by histamine prick test-induced itch. J. Invest. Dermatol. 125:380-382.
46. Kringelbach, M.L. 2005. The human orbitofrontal cortex: linking reward to hedonic experience. Nat. Rev. Neurosci. 6:691-702.
47. Zubieta, J.K., et al. 2003. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science. 299:1240-1243.
48. Nilsson, H.J., Levinsson, A., and Schouenborg, J. 1997. Cutaneous field stimulation (CFS): a new powerful method to combat itch. Pain. 71:49-55.
49. Yosipovitch, G., Fast, K., and Bernhard, J.D. 2005. Noxious heat and scratching decrease histamine-induced itch and skin blood flow. J. Invest. Dermatol. 125:1268-1272.
50. Atanassoff, P.G., et al. 1999. Enhancement of experimental pruritus and mechanically evoked dysesthesiae with local anesthesia. Somatosens. Mot. Res. 16:291-298.
51. McRae, C.A., et al. 2003. Pain as a complication of use of opiate antagonists for symptom control in cholestasis. Gastroenterology. 125:591-596.
52. Jones, E.A., Neuberger, J., and Bergasa, N.V. 2002. Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. QJM. 95:547-552.
53. Stein, C., Schafer, M., and Machelska, H. 2003. Attacking pain at its source: new perspectives on opioids. Nat. Med. 9:1003-1008.
54. DeHaven-Hudkins, D.L., et al. 2002. Antipruritic and antihyperalgesic actions of loperamide and analogs. Life Sci. 71:2787-2796.
55. Bigliardi-Qi, M., Lipp, B., Sumanovski, L.T., Buechner, S.A., and Bigliardi, P.L. 2005. Changes of epidermal mu-opiate receptor expression and nerve endings in chronic atopic dermatitis. Dermatology. 210:91-99.
56. Ikoma, A., et al. 2003. Neuronal sensitization for histamine-induced itch in lesional skin of patients with atopic dermatitis. Arch. Dermatol. 139:1455-1458.
57. Amadesi, S., et al. 2004. Protease-activated receptor 2 sensitizes the capsaicin receptor transient receptor potential vanilloid receptor 1 to induce hyperalgesia. J. Neurosci. 24:4300-4312.
58. Moormann, C., et al. 2006. Functional characterization and expression analysis of the proteinase-activated receptor-2 in human cutaneous mast cells. J. Invest. Dermatol. 126:746-755.
59. Steinhoff, M., et al. 2003. Modern aspects of cutaneous neurogenic inflammation. Arch. Dermatol. 139:1479-1488.
60. Steinhoff, M., et al. 2005. Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr. Rev. 26:1-43.
61. Vergnolle, N., Ferazzini, M., D'Andrea, M.R., Buddenkotte, J., and Steinhoff, M. 2003. Proteinase-activated receptors: novel signals for peripheral nerves. Trends Neurosci. 26:496-500.
62. Szolcsanyi, J. 2004. Forty years in capsaicin research for sensory pharmacology and physiology. Neuropeptides. 38:377-384.
63. Grassberger, M., Steinhoff, M., Schneider, D., and Luger, T.A. 2004. Pimecrolimus - an anti-inflammatory drug targeting the skin. Exp. Dermatol. 13:721-730.
64. Steinhoff, M., et al. 2000. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat. Med. 6:151-158.
65. Vergnolle, N., et al. 2001. Proteinase-activated receptor-2 and hyperalgesia: a novel pain pathway. Nat. Med. 7:821-826.
66. Ossovskaya, V.S., and Bunnett, N.W. 2004. Protease-activated receptors: contribution to physiology and disease. Physiol. Rev. 84:579-621.
67. Su, X., Camerer, E., Hamilton, J.R., Coughlin, S.R., and Matthay, M.A. 2005. Protease-activated receptor-2 activation induces acute lung inflammation by neuropeptide-dependent mechanisms. J. Immunol. 175:2598-2605.
68. Shelley, W.B., and Arthur, R.P. 1955. Mucunain, the active pruritogenic proteinase of cowhage. Science. 122:469-470.
69. Obreja, O., Rukwied, R., Steinhoff, M., and Schmelz, M. 2006. Neurogenic components of trypsin- and thrombin-induced inflammation in rat skin, in vivo. Exp. Dermatol. 15:58-65.
70. Steen, K.H., Steen, A.E., and Reeh, P.W. 1995. A dominant role of acid pH in inflammatory excitation and sensitization of nociceptors in rat skin, in vitro. J. Neurosci. 15:3982-3989.
71. Gieler, U., Kupfer, J., Niemeier, V., and Brosig, B. 2003. Psyche and skin: what's new? J. Eur. Acad. Dermatol. Venereol. 17:128-130.
72. Slominski, A., and Wortsman, J. 2000. Neuroendocrinology of the skin. Endocr. Rev. 21:457-487.
73. McEwen, B., and Lasley, E.N. 2004. The end of stress as we know it. Dana Press. Washington, DC, USA. 239 pp.
74. Willer, J.C., Dehen, H., and Cambier, J. 1981. Stress-induced analgesia in humans: endogenous opioids and naloxone-reversible depression of pain reflexes. Science. 212:689-691.
75. Vaughan, C.W. 2005. Stressed-out endogenous cannabinoids relieve pain. Trends Pharmacol. Sci. 27:69-71.
76. Niemeier, V., Nippesen, M., Kupfer, J., Schill, W.B., and Gieler, U. 2002. Psychological factors associated with hand dermatoses: which subgroup needs additional psychological care? Br. J. Dermatol. 146:1031-1037.
77. Flor, H., Knost, B., and Birbaumer, N. 2002. The role of operant conditioning in chronic pain: an experimental investigation. Pain. 95:111-118.
78. Hwang, S.W., et al. 2000. Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc. Natl. Acad. Sci. U. S. A. 97:6155-6160.
79. Chuang, H.H., et al. 2001. Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition. Nature. 411:957-962.
80. Shin, J., et al. 2002. Bradykinin-12-lipoxygenase-VR1 signaling pathway for inflammatory hyperalgesia. Proc. Natl. Acad. Sci. U. S. A. 99:10150-10155.
81. Mohapatra, D.P., and Nau, C. 2003. Desensitization of capsaicin-activated currents in the vanilloid receptor TRPV1 is decreased by the cyclic AMP-dependent protein kinase pathway. J. Biol. Chem. 278:50080-50090.
82. Di Marzo, V., Blumberg, P.M., and Szallasi, A. 2002. Endovanilloid signaling in pain. Curr. Opin. Neurobiol. 12:372-379.
83. Caterina, M.J., et al. 1997. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 389:816-824.
84. Caterina, M.J., and Julius, D. 2001. The vanilloid receptor: a molecular gateway to the pain pathway. Annu. Rev. Neurosci. 24:487-517.
85. Clapham, D.E. 2003. TRP channels as cellular sensors. Nature. 426:517-524.
86. Weisshaar, E., Heyer, G., Forster, C., and Handwerker, H.O. 1998. Effect of topical capsaicin on the cutaneous reactions and itching to histamine in atopic eczema compared to healthy skin. Arch. Dermatol. Res. 290:306-311.
87. Biro, T., Acs, G., Acs, P., Modarres, S., and Blumberg, P.M. 1997. Recent advances in understanding of vanilloid receptors: a therapeutic target for treatment of pain and inflammation in skin. J. Investig. Dermatol. Symp. Proc. 2:56-60.
88. Inoue, K., Koizumi, S., Fuziwara, S., Denda, S., and Denda, M. 2002. Functional vanilloid receptors in cultured normal human epidermal keratinocytes. Biochem. Biophys. Res. Commun. 291:124-129.
89. Bodo, E., et al. 2004. Vanilloid receptor-1 (VR1) is widely expressed on various epithelial and mesenchymal cell types of human skin. J. Invest. Dermatol. 123:410-413.
90. Stander, S., et al. 2004. Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp. Dermatol. 13:129-139.
91. Southall, M.D., et al. 2003. Activation of epidermal vanilloid receptor-1 induces release of proinflammatory mediators in human keratinocytes. J. Pharmacol. Exp. Ther. 304:217-222.
92. Bodo, E., et al. 2005. A hot new twist to hair biology: involvement of vanilloid receptor-1 (VR1/TRPV1) signaling in human hair growth control. Am. J. Pathol. 166:985-998.
93. Stander, S., Luger, T., and Metze, D. 2001. Treatment of prurigo nodularis with topical capsaicin. J. Am. Acad. Dermatol. 44:471-478.
94. Klein, T.W. 2005. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol. 5:400-411.
95. Dvorak, M., Watkinson, A., McGlone, F., and Rukwied, R. 2003. Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. Inflamm. Res. 52:238-245.
96. Singh, M.E., McGregor, I.S., and Mallet, P.E. 2005. Repeated exposure to Delta(9)-tetrahydrocannabinol alters heroin-induced locomotor sensitisation and Fos-immunoreactivity. Neuropharmacology. 49:1189-1200.
97. Akerman, S., Kaube, H., and Goadsby, P.J. 2004. Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors. Br. J. Pharmacol. 142:1354-1360.
98. van der Stelt, M., et al. 2005. Anandamide acts as an intracellular messenger amplifying Ca(2+) influx via TRPV1 channels. EMBO J. 24:3517-3518.
99. Maccarrone, M., et al. 2003. The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermal differentiation through CB1 receptor-dependent inhibition of protein kinase C, activation protein-1, and transglutaminase. J. Biol. Chem. 278:33896-33903.
100. Stander, S., Schmelz, M., Metze, D., Luger, T., and Rukwied, R. 2005. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J. Dermatol. Sci. 38:177-188.
101. Richardson, J.D., Kilo, S., and Hargreaves, K.M. 1998. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain. 75:111-119.
102. Rukwied, R., Watkinson, A., McGlone, F., and Dvorak, M. 2003. Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain. 102:283-288.
103. Caterina, M.J., Rosen, T.A., Tominaga, M., Brake, A.J., and Julius, D. 1999. A capsaicin-receptor homologue with a high threshold for noxious heat. Nature. 398:436-441.
104. Peier, A.M., et al. 2002. A heat-sensitive TRP channel expressed in keratinocytes. Science. 296:2046-2049.
105. Smith, G.D., et al. 2002. TRPV3 is a temperature-sensitive vanilloid receptor-like protein. Nature. 418:186-190.
106. Chung, M.K., Lee, H., Mizuno, A., Suzuki, M., and Caterina, M.J. 2004. TRPV3 and TRPV4 mediate warmth-evoked currents in primary mouse keratinocytes. J. Biol. Chem. 279:21569-21575.
107. Stokes, A.J., Shimoda, L.M., Koblan-Huberson, M., Adra, C.N., and Turner, H. 2004. A TRPV2-PKA signaling module for transduction of physical stimuli in mast cells. J. Exp. Med. 200:137-147.
108. Moqrich, A., et al. 2005. Impaired thermosensation in mice lacking TRPV3, a heat and camphor sensor in the skin. Science. 307:1468-1472.
109. Watanabe, H., et al. 2003. Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature. 424:434-438.
110. McKemy, D.D., Neuhausser, W.M., and Julius, D. 2002. Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature. 416:52-58.
111. Schmelz, M., Schmid, R., Handwerker, H.O., and Torebjork, H.E. 2000. Encoding of burning pain from capsaicin-treated human skin in two categories of unmyelinated nerve fibres. Brain. 123:560-571.
112. Slominski, A.T., et al. 1999. Cutaneous expression of CRH and CRH-R. Is there a "skin stress response system?" Ann. N. Y. Acad. Sci. 885:287-311.
113. Sonkoly, E., et al. 2006. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J. Allergy Clin. Immunol. 117:411-417.
114. Steinhoff, M., et al. 2003. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J. Neurosci. 23:6176-6180.
115. Roosterman, D., Cottrell, G.S., Schmidlin, F., Steinhoff, M., and Bunnett, N.W. 2004. Recycling and resensitization of the neurokinin 1 receptor. Influence of agonist concentration and Rab GTPases. J. Biol. Chem. 279:30670-30679.
116. Stander, S., et al. 2003. Neurophysiology of pruritus: cutaneous elicitation of itch. Arch. Dermatol. 139:1463-1470.
117. Blunk, J.A., et al. 2004. Opioid-induced mast cell activation and vascular responses is not mediated by mu-opioid receptors: an in vivo microdialysis study in human skin. Anesth. Analg. 98:364-370, table of contents.
118. Neisius, U., Olsson, R., Rukwied, R., Lischetzki, G., and Schmelz, M. 2002. Prostaglandin E2 induces vasodilation and pruritus, but no protein extravasation in atopic dermatitis and controls. J. Am. Acad. Dermatol. 47:28-32.
119. Yesudian, P.D., and Wilson, N.J. 2005. Efficacy of gabapentin in the management of pruritus of unknown origin. Arch. Dermatol. 141:1507-1509.
120. Horiuchi, Y., Bae, S., and Katayama, I. 2005. Nerve growth factor (NGF) and epidermal nerve fibers in atopic dermatitis model NC/Nga mice. J. Dermatol. Sci. 39:56-58.
121. Ashida, Y., Denda, M., and Hirao, T. 2001. Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J. Invest. Dermatol. 116:261-265.
122. Miyamoto, T., Nojima, H., Shinkado, T., Nakahashi, T., and Kuraishi, Y. 2002. Itch-associated response induced by experimental dry skin in mice. Jpn. J. Pharmacol. 88:285-292.
123. Peier, A.M., et al. 2002. A TRP channel that senses cold stimuli and menthol. Cell. 108:705-715.
124. Xu, H., et al. 2002. TRPV3 is a calcium-permeable temperature-sensitive cation channel. Nature. 418:181-186.
125. Brain, S.D. 2000. New feelings about the role of sensory nerves in inflammation. Nat. Med. 6:134-135.